Physicians' Academy for Cardiovascular Education

Stroke

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

AF patients with cognitive impairment or frailty less likely to receive OAC

Literature - Feb. 12, 2019 - Madhavan M et al. - Am Heart J 2019

In the ORBIT-AF multicenter cohort study, AF patients with cognitive impairment or frailty showed higher stroke risk and mortality, but OACs were underprescribed. The conditions did not affect OAC treatment effect.

Large reduction of major vascular events with statins in older individuals

Literature - Feb. 11, 2019 - Cholesterol Treatment Trialists’ Collaboration - The Lancet 2019

A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.

Combination of DOAC with aspirin effective for prevention of stroke in patients with CAD or PAD

Literature - Feb. 5, 2019 - Sharma M et al. - Circulation 2019

Low-dose rivaroxaban plus aspirin reduced the risk for stroke in patients with CAD or PAD, especially in those with prior stroke, as shown in a subanalysis of the COMPASS trial.

Reduced CV events with loading dose of statin before PCI in patients with ACS

Literature - Jan. 28, 2019 - Ye Z et al. - Eur Heart J 2019

A meta-analysis of 13 randomized controlled trials showed that a loading dose of atorvastatin before PCI markedly reduced MACE in patients with ACS.

Greater net clinical benefit of NOAC vs. warfarin in Asians with AF compared with non-Asians

Literature - Jan. 15, 2019 - Chao TF et al. - Eur Heart J 2018

A post-hoc analysis of ENGAGE AF-TIMI 48 showed comparable efficacy, favorable safety, and better net clinical outcomes with edoxaban vs. warfarin in Asians, compared to non-Asians.

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

Summary | SGLT2 inhibition in cardiology: What is the profile of benefit?

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

For primary prevention, statins provide net benefits at higher than recommended 10-year risks

Literature - Dec. 17, 2018 - Yebyo HG et al. - Ann Intern Med 2018

In a quantitative modeling study, statins provided net benefit at higher 10-year risks for CVD than seen in most guidelines. The level of CVD risk at which net benefit occurs depends on age, sex, and statin type.

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

DOAC treatment safe and effective in AF despite multi-morbidity

Literature - Dec. 4, 2018 - Alexander KP et al. - American Heart Journal 2018

A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.